Fresenius stock gains 1.85 percent as Q2 earnings improve

Published on 09/28/2026 at 11:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius raised 2026 core EPS growth guidance to 10%-15% after Q2 2026. Group EBIT margin reached 12.3 percent, while market capitalization stood at EUR 26.5 billion.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE0005785604) was trading at EUR 47.01 on Xetra on September 28, 2026, up 1.85 percent from the prior close of EUR 46.15. The move follows a second-quarter performance that lifted full-year core EPS growth guidance to 10%-15%.

Q2 revenue reaches EUR 5.864 billion

According to Fresenius, Q2 2026 group revenue before special items rose 6 percent to EUR 5.864 billion from EUR 5.571 billion in Q2 2025. The comparison is based on organic growth adjusted for accounting effects related to hyperinflation in Argentina.

Group EBIT increased 10 percent to EUR 719 million from EUR 654 million, while core net income climbed 14 percent to EUR 470 million from EUR 412 million. Core EPS advanced 14 percent to EUR 0.83 from EUR 0.73, giving the earnings improvement a direct per-share effect.

Guidance moves to 10%-15% growth

In the Q2 2026 earnings call on August 5, 2026, Yahoo Finance reported that Fresenius lifted its full-year core EPS growth guidance from 5%-10% to 10%-15% at constant currency. The group EBIT margin improved by 60 basis points year over year to 12.3 percent.

The operating mix adds a second dimension to the guidance increase. Kabi delivered 7 percent organic revenue growth in Q2, with its growth vectors rising 12 percent, while Helios posted 5 percent organic revenue growth and a 10.6 percent EBIT margin, according to the companys Q2 figures.

Fresenius also linked the stronger outlook to its biopharma platform. Biopharma organic revenue growth reached 38 percent in Q2, while growth vectors delivered a 17.9 percent margin, up 360 basis points from the prior-year quarter.

Stock remains below its 52-week high

The Xetra quote stood within a daily range of EUR 46.35 to EUR 47.18 on September 28, 2026. Its 52-week range extended from EUR 35.11 to EUR 52.96, placing the current price EUR 5.95 below the yearly high and EUR 11.90 above the low.

Market capitalization stood at EUR 26.5 billion on September 28, 2026, with trading volume at 114,823 shares. Investing.com lists November 4, 2026, as the next earnings date.

Fresenius stock trades at EUR 47.01

For investors, the central contrast is clear: Fresenius stock was up 1.85 percent on September 28, 2026, while the latest operating figures show double-digit growth in EBIT, core net income and core EPS.